Holen Sie sich die Stockscreener-App
6.44
2.22%
0.14
Handel nachbörslich:
6.44
Schlusskurs vom Vortag:
$6.30
Offen:
$6.29
24-Stunden-Volumen:
468.00K
Relative Volume:
1.09
Marktkapitalisierung:
$427.34M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-10.73
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
-2.42%
1M Leistung:
-1.68%
6M Leistung:
-36.17%
1J Leistung:
-12.50%
1-Tages-Spanne:
$6.29
$6.59
1-Wochen-Bereich:
$6.26
$6.77
52-Wochen-Spanne:
$6.02
$14.38
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Vergleichen Sie BVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.44 | 437.96M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Bioventus Inc. Stock Analysis and ForecastExplosive earning power - jammulinksnews.com
What analysts say about Bioventus Inc. stockExplosive market performance - Autocar Professional
What drives Bioventus Inc. stock priceAccelerated wealth building - jammulinksnews.com
Is Bioventus Inc. a good long term investmentUnstoppable trading performance - Autocar Professional
Bioventus (NASDAQ:BVS) Cut to “Buy” at Wall Street Zen - Defense World
Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating - MSN
Bioventus (NASDAQ:BVS) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Analysts Expect Bioventus Inc. (NASDAQ:BVS) To Breakeven Soon - simplywall.st
What makes Bioventus Inc. stock price move sharplyFree Best Performing Stock Alerts - beatles.ru
why bioventus inc. stock attracts strong analyst attentionWeekly Big Movers - newser.com
How Bioventus Inc. stock performs during market volatilityBreakout Momentum Stocks - beatles.ru
Why Bioventus Inc. stock attracts strong analyst attentionFree Stock Market Strategy Classes - Newser
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
Allspring Global Investments Holdings LLC Raises Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
With 36% stake, Bioventus Inc. (NASDAQ:BVS) seems to have captured institutional investors' interest - Yahoo Finance
How the (BVS) price action is used to our Advantage - news.stocktradersdaily.com
Bioventus(BVS) Shares Soar 3.54% on Pipeline Progress - AInvest
Cantor Fitzgerald Initiates Coverage on Bioventus (NYSE:BVS) - Defense World
Cantor Fitzgerald initiates Bioventus stock with Overweight rating on growth potential By Investing.com - Investing.com South Africa
Cantor Fitzgerald initiates Bioventus stock with Overweight rating on growth potential - Investing.com Nigeria
Cartilage Repair Regeneration Market is Going To Boom | Zimmer Biomet, Bioventus - newstrail.com
Bioventus' Bold Bet on Core Markets: A Strategic Shift With High Stakes - AInvest
BVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
(BVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Do Options Traders Know Something About Bioventus Stock We Don't? - The Globe and Mail
(BVS) Proactive Strategies - news.stocktradersdaily.com
Bone Growth Stimulator Market Booming Worldwide with - openPR.com
bioventus inc. reports results of annual stockholders meeting By Investing.com - Investing.com South Africa
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):